GlassScriptPhysician profile
Hazem Tabbaa
NPI 1619393477
$2,495.59
in general payments reported to CMS, 2019-2025
18 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2021: $97.03 · 2022: $506 · 2023: $599 · 2024: $749 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,654 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,653.70 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $895.92 | 2019-2025 | Mavyret, Rinvoq, Skyrizi |
| Boston Scientific Corporation | $405.05 | 2021-2024 | Apollo Esg Nxt System |
| Takeda Pharmaceuticals U.S.A., INC. | $351.56 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.04 | 2022-2025 | Xifaxan |
| Janssen Biotech, INC. | $123.08 | 2023-2024 | Stelara, Tremfya, Simponi |
| Endogastric Solutions, INC | $73.68 | 2022-2024 | Esophyx |
| Qol Medical, LLC | $62.56 | 2024 | Sucraid |
| Gilead Sciences, INC. | $60.67 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $60.39 | 2022-2025 | Dupixent |
| Celgene Corporation | $51.52 | 2022-2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $51.46 | 2022 | |
| Braintree Laboratories, INC. | $46.59 | 2022 | |
| Intercept Pharmaceuticals, INC. | $33.27 | 2024 | |
| Ardelyx, INC. | $33.14 | 2023 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $29.51 | 2023 | Zeposia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $22.82 | 2024 | |
| Lilly USA, LLC | $20.85 | 2025 | Omvoh |
| Travere Therapeutics, INC. | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hazem Tabbaa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.